JP2009520685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009520685A5 JP2009520685A5 JP2008541110A JP2008541110A JP2009520685A5 JP 2009520685 A5 JP2009520685 A5 JP 2009520685A5 JP 2008541110 A JP2008541110 A JP 2008541110A JP 2008541110 A JP2008541110 A JP 2008541110A JP 2009520685 A5 JP2009520685 A5 JP 2009520685A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- heterocycloalkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 72
- 125000003118 aryl group Chemical group 0.000 claims 70
- 125000001072 heteroaryl group Chemical group 0.000 claims 70
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 69
- 125000000753 cycloalkyl group Chemical group 0.000 claims 63
- 125000003710 aryl alkyl group Chemical group 0.000 claims 57
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 51
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 44
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 44
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 34
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 32
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 32
- 125000005843 halogen group Chemical group 0.000 claims 27
- 229910052799 carbon Inorganic materials 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 11
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- -1 (3′-methoxybiphenyl-3-yl) -1′H-spiro [cyclohexane-1,2′-quinazoline] -4′-amine trifluoroacetate Chemical compound 0.000 claims 1
- QDMVACSUPDWDLL-UHFFFAOYSA-N 1'-[3-(3-methoxyphenyl)phenyl]spiro[1h-quinazoline-2,3'-cyclohexene]-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C=2CCCC3(C=2)N=C(N)C2=CC=CC=C2N3)=C1 QDMVACSUPDWDLL-UHFFFAOYSA-N 0.000 claims 1
- ZFEGUWVJFDUVCO-UHFFFAOYSA-N 1-amino-3-(3-bromophenyl)-3-(trifluoromethyl)-4h-isoquinoline-6-carbonitrile Chemical compound C1C2=CC(C#N)=CC=C2C(N)=NC1(C(F)(F)F)C1=CC=CC(Br)=C1 ZFEGUWVJFDUVCO-UHFFFAOYSA-N 0.000 claims 1
- NJNNIZZZQLHDQT-UHFFFAOYSA-N 1-amino-3-(3-bromophenyl)-3-(trifluoromethyl)-4h-isoquinoline-6-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC(C(=O)N)=CC=C2C(N)=NC1(C(F)(F)F)C1=CC=CC(Br)=C1 NJNNIZZZQLHDQT-UHFFFAOYSA-N 0.000 claims 1
- GGANFIZMIYZCQB-UHFFFAOYSA-N 1-amino-3-[3-(3-methoxyphenyl)phenyl]-3-(trifluoromethyl)-4h-isoquinoline-6-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(N=C(N)C3=CC=C(C=C3C2)C#N)C(F)(F)F)=C1 GGANFIZMIYZCQB-UHFFFAOYSA-N 0.000 claims 1
- AMIKLZSNQVTNNN-UHFFFAOYSA-N 1-amino-3-[3-(3-methoxyphenyl)phenyl]-3-(trifluoromethyl)-4h-isoquinoline-6-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(N=C(N)C3=CC=C(C=C3C2)C(N)=O)C(F)(F)F)=C1 AMIKLZSNQVTNNN-UHFFFAOYSA-N 0.000 claims 1
- DBEQWEKSSBSANW-UHFFFAOYSA-N 1-amino-3-[3-(3-methoxyphenyl)phenyl]-3-(trifluoromethyl)-4h-isoquinoline-6-carboxylic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(N=C(N)C3=CC=C(C=C3C2)C(O)=O)C(F)(F)F)=C1 DBEQWEKSSBSANW-UHFFFAOYSA-N 0.000 claims 1
- RXVNKLSJBYVTPV-UHFFFAOYSA-N 1-amino-3-phenyl-3-(trifluoromethyl)-4H-isoquinoline-6-carbonitrile hydrochloride Chemical compound Cl.C1C2=CC(C#N)=CC=C2C(N)=NC1(C(F)(F)F)C1=CC=CC=C1 RXVNKLSJBYVTPV-UHFFFAOYSA-N 0.000 claims 1
- IDGGKHZOFFZFNT-UHFFFAOYSA-N 1-amino-3-phenyl-3-(trifluoromethyl)-4h-isoquinoline-6-carboxylic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC(C(O)=O)=CC=C2C(N)=NC1(C(F)(F)F)C1=CC=CC=C1 IDGGKHZOFFZFNT-UHFFFAOYSA-N 0.000 claims 1
- HICQWLMPQMJNOW-UHFFFAOYSA-N 2-(3-bromophenyl)-2-methyl-1,3-benzoxazin-4-amine Chemical compound O1C2=CC=CC=C2C(N)=NC1(C)C1=CC=CC(Br)=C1 HICQWLMPQMJNOW-UHFFFAOYSA-N 0.000 claims 1
- CVEMAFPNUJWPBK-UHFFFAOYSA-N 2-(3-bromophenyl)-2-methyl-1h-quinazolin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1C2=CC=CC=C2C(N)=NC1(C)C1=CC=CC(Br)=C1 CVEMAFPNUJWPBK-UHFFFAOYSA-N 0.000 claims 1
- CBDCPWBARIEQJW-UHFFFAOYSA-N 2-(3-bromophenyl)-2-methyl-3h-1,3-benzoxazin-4-one Chemical compound N1C(=O)C2=CC=CC=C2OC1(C)C1=CC=CC(Br)=C1 CBDCPWBARIEQJW-UHFFFAOYSA-N 0.000 claims 1
- OBIOITWOYDDXBX-UHFFFAOYSA-N 2-(3-bromophenyl)-4-chloro-2-methyl-1,3-benzoxazine Chemical compound O1C2=CC=CC=C2C(Cl)=NC1(C)C1=CC=CC(Br)=C1 OBIOITWOYDDXBX-UHFFFAOYSA-N 0.000 claims 1
- IFKZSHQHLMNYJN-UHFFFAOYSA-N 2-(3-bromophenyl)-n-methoxy-2-methyl-1,3-benzoxazin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O1C2=CC=CC=C2C(NOC)=NC1(C)C1=CC=CC(Br)=C1 IFKZSHQHLMNYJN-UHFFFAOYSA-N 0.000 claims 1
- UANBHJOGMLSYJJ-UHFFFAOYSA-N 2-[2-(3-bromophenyl)ethyl]-2-methyl-1,3-benzoxazin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O1C2=CC=CC=C2C(N)=NC1(C)CCC1=CC=CC(Br)=C1 UANBHJOGMLSYJJ-UHFFFAOYSA-N 0.000 claims 1
- ASJPNAGKSRTSOU-UHFFFAOYSA-N 2-[2-(3-bromophenyl)ethyl]-2-methyl-1h-quinazolin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1C2=CC=CC=C2C(N)=NC1(C)CCC1=CC=CC(Br)=C1 ASJPNAGKSRTSOU-UHFFFAOYSA-N 0.000 claims 1
- SORJLLJWDWPORX-UHFFFAOYSA-N 2-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-1,2-dimethylquinazolin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3(C)N(C4=CC=CC=C4C(N)=N3)C)C=CC=2)=C1 SORJLLJWDWPORX-UHFFFAOYSA-N 0.000 claims 1
- IVZRBDBEWXWNCG-UHFFFAOYSA-N 2-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-2-methyl-1,3-benzoxazin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3(C)N=C(N)C4=CC=CC=C4O3)C=CC=2)=C1 IVZRBDBEWXWNCG-UHFFFAOYSA-N 0.000 claims 1
- NCSVTMDNYOUHMB-UHFFFAOYSA-N 2-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-2-methyl-1h-quinazolin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3(C)N=C(N)C4=CC=CC=C4N3)C=CC=2)=C1 NCSVTMDNYOUHMB-UHFFFAOYSA-N 0.000 claims 1
- YQYFQGAKNKITRN-UHFFFAOYSA-N 2-[3-(3-methoxyphenyl)phenyl]-2-methyl-1,3-benzoxazin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(C)N=C(N)C3=CC=CC=C3O2)=C1 YQYFQGAKNKITRN-UHFFFAOYSA-N 0.000 claims 1
- WAYHGSVZWAQZSE-UHFFFAOYSA-N 2-[3-(3-methoxyphenyl)phenyl]-2-methyl-1h-quinazolin-4-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(C)N=C(N)C3=CC=CC=C3N2)=C1 WAYHGSVZWAQZSE-UHFFFAOYSA-N 0.000 claims 1
- GUZQPEQUNBMUCL-UHFFFAOYSA-N 3-(3-bromophenyl)-1-ethylsulfanyl-3-methyl-4h-isoquinoline Chemical compound C1C2=CC=CC=C2C(SCC)=NC1(C)C1=CC=CC(Br)=C1 GUZQPEQUNBMUCL-UHFFFAOYSA-N 0.000 claims 1
- CDVOQPAKADWWQB-UHFFFAOYSA-N 3-(3-bromophenyl)-3,4-dihydroisoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC=CC=C2C(N)=NC1C1=CC=CC(Br)=C1 CDVOQPAKADWWQB-UHFFFAOYSA-N 0.000 claims 1
- HMUSTCPHRCSDBS-UHFFFAOYSA-N 3-(3-bromophenyl)-3-(trifluoromethyl)-4h-isoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC=CC=C2C(N)=NC1(C(F)(F)F)C1=CC=CC(Br)=C1 HMUSTCPHRCSDBS-UHFFFAOYSA-N 0.000 claims 1
- IZGOILZIFQOLCH-UHFFFAOYSA-N 3-(3-phenylphenyl)-3,4-dihydroisoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC=CC=C2C(N)=NC1C(C=1)=CC=CC=1C1=CC=CC=C1 IZGOILZIFQOLCH-UHFFFAOYSA-N 0.000 claims 1
- GTMLVVUMMNMOPR-UHFFFAOYSA-N 3-[2-(3-bromophenyl)ethyl]-3-methyl-4h-isoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC=CC=C2C(N)=NC1(C)CCC1=CC=CC(Br)=C1 GTMLVVUMMNMOPR-UHFFFAOYSA-N 0.000 claims 1
- MMSHNXHHAKRLCP-UHFFFAOYSA-N 3-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3-methyl-4h-isoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3(C)N=C(N)C4=CC=CC=C4C3)C=CC=2)=C1 MMSHNXHHAKRLCP-UHFFFAOYSA-N 0.000 claims 1
- HOPNUIGTNSSOGT-UHFFFAOYSA-N 3-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3-phenyl-4h-isoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3(N=C(N)C4=CC=CC=C4C3)C=3C=CC=CC=3)C=CC=2)=C1 HOPNUIGTNSSOGT-UHFFFAOYSA-N 0.000 claims 1
- YRWAUSCCJAWRNU-UHFFFAOYSA-N 3-[3-(3-methoxyphenyl)phenyl]-3,4-dihydroisoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2N=C(N)C3=CC=CC=C3C2)=C1 YRWAUSCCJAWRNU-UHFFFAOYSA-N 0.000 claims 1
- BVPXFERMHNAQCD-UHFFFAOYSA-N 3-[3-(3-methoxyphenyl)phenyl]-3-(trifluoromethyl)-4h-isoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(N=C(N)C3=CC=CC=C3C2)C(F)(F)F)=C1 BVPXFERMHNAQCD-UHFFFAOYSA-N 0.000 claims 1
- XQRYHJYTPLAAOZ-UHFFFAOYSA-N 3-methyl-3-(3-phenylphenyl)-4h-isoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC=CC=C2C(N)=NC1(C)C(C=1)=CC=CC=1C1=CC=CC=C1 XQRYHJYTPLAAOZ-UHFFFAOYSA-N 0.000 claims 1
- UNSMGVCQMIQVKA-UHFFFAOYSA-N 3-methyl-5-trimethylsilylthiophene-2-carbonitrile Chemical compound CC=1C=C([Si](C)(C)C)SC=1C#N UNSMGVCQMIQVKA-UHFFFAOYSA-N 0.000 claims 1
- RTJBVUVZUZULEL-UHFFFAOYSA-N 3-phenyl-3-(trifluoromethyl)-4h-isoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC=CC=C2C(N)=NC1(C(F)(F)F)C1=CC=CC=C1 RTJBVUVZUZULEL-UHFFFAOYSA-N 0.000 claims 1
- KSNHYZMGOLDAAD-UHFFFAOYSA-N 3-phenyl-6-(2h-tetrazol-5-yl)-3-(trifluoromethyl)-4h-isoquinolin-1-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C2C(N)=NC(C(F)(F)F)(C=3C=CC=CC=3)CC2=CC=1C1=NN=NN1 KSNHYZMGOLDAAD-UHFFFAOYSA-N 0.000 claims 1
- OVYSOCDQHHFLLW-UHFFFAOYSA-N 4-amino-2-[2-(3-bromophenyl)ethyl]-2-methyl-1h-quinazoline-7-carboxylic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1C2=CC(C(O)=O)=CC=C2C(N)=NC1(C)CCC1=CC=CC(Br)=C1 OVYSOCDQHHFLLW-UHFFFAOYSA-N 0.000 claims 1
- YYZVPIDGLYBUAJ-UHFFFAOYSA-N 4-amino-2-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-2-methyl-1h-quinazoline-7-carboxylic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(CCC3(C)N=C(N)C4=CC=C(C=C4N3)C(O)=O)C=CC=2)=C1 YYZVPIDGLYBUAJ-UHFFFAOYSA-N 0.000 claims 1
- XHKQMNMOWLESNO-UHFFFAOYSA-N 5-(3-bromophenyl)-2-trimethylsilyl-4,5-dihydrothieno[2,3-c]pyridin-7-amine Chemical compound N1=C(N)C=2SC([Si](C)(C)C)=CC=2CC1C1=CC=CC(Br)=C1 XHKQMNMOWLESNO-UHFFFAOYSA-N 0.000 claims 1
- IGMQUPUPIVTFBY-UHFFFAOYSA-N 5-(3-bromophenyl)-4,5-dihydrothieno[2,3-c]pyridin-7-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C=2C=CSC=2C(N)=NC1C1=CC=CC(Br)=C1 IGMQUPUPIVTFBY-UHFFFAOYSA-N 0.000 claims 1
- FDRKMWYKESHPNS-UHFFFAOYSA-N 5-(3-bromophenyl)-5-(trifluoromethyl)-2-trimethylsilyl-4h-thieno[2,3-c]pyridin-7-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)C=2SC([Si](C)(C)C)=CC=2CC1(C(F)(F)F)C1=CC=CC(Br)=C1 FDRKMWYKESHPNS-UHFFFAOYSA-N 0.000 claims 1
- JENRFFTXYHALCY-UHFFFAOYSA-N 5-(3-bromophenyl)-5-(trifluoromethyl)-4h-thieno[2,3-c]pyridin-7-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C=2C=CSC=2C(N)=NC1(C(F)(F)F)C1=CC=CC(Br)=C1 JENRFFTXYHALCY-UHFFFAOYSA-N 0.000 claims 1
- SZIYTRZVMUIROZ-UHFFFAOYSA-N 5-[3-(3-methoxyphenyl)phenyl]-4,5-dihydrothieno[2,3-c]pyridin-7-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2N=C(N)C=3SC=CC=3C2)=C1 SZIYTRZVMUIROZ-UHFFFAOYSA-N 0.000 claims 1
- GAHWLYOYDYMKPM-UHFFFAOYSA-N 5-[3-(3-methoxyphenyl)phenyl]-5-(trifluoromethyl)-4h-thieno[2,3-c]pyridin-7-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C=2C=C(C=CC=2)C2(N=C(N)C=3SC=CC=3C2)C(F)(F)F)=C1 GAHWLYOYDYMKPM-UHFFFAOYSA-N 0.000 claims 1
- OCHYFOFDNRHDRX-UHFFFAOYSA-N 5-phenyl-5-(trifluoromethyl)-2-trimethylsilyl-4h-thieno[2,3-c]pyridin-7-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N)C=2SC([Si](C)(C)C)=CC=2CC1(C(F)(F)F)C1=CC=CC=C1 OCHYFOFDNRHDRX-UHFFFAOYSA-N 0.000 claims 1
- UIRYHPCELAYYKQ-UHFFFAOYSA-N 5-phenyl-5-(trifluoromethyl)-4h-thieno[2,3-c]pyridin-7-amine Chemical compound C1C=2C=CSC=2C(N)=NC1(C(F)(F)F)C1=CC=CC=C1 UIRYHPCELAYYKQ-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- KMSJFRPNIYWPMV-UHFFFAOYSA-N n-[[1-amino-3-phenyl-3-(trifluoromethyl)-4h-isoquinolin-6-yl]methyl]acetamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC(CNC(=O)C)=CC=C2C(N)=NC1(C(F)(F)F)C1=CC=CC=C1 KMSJFRPNIYWPMV-UHFFFAOYSA-N 0.000 claims 1
- UMTXFOGGWYZSOA-UHFFFAOYSA-N n-[[1-amino-3-phenyl-3-(trifluoromethyl)-4h-isoquinolin-6-yl]methyl]methanesulfonamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C2=CC(CNS(=O)(=O)C)=CC=C2C(N)=NC1(C(F)(F)F)C1=CC=CC=C1 UMTXFOGGWYZSOA-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73732705P | 2005-11-15 | 2005-11-15 | |
| PCT/SE2006/001283 WO2007058583A2 (en) | 2005-11-15 | 2006-11-13 | Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009520685A JP2009520685A (ja) | 2009-05-28 |
| JP2009520685A5 true JP2009520685A5 (enExample) | 2010-01-07 |
Family
ID=38049090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541110A Pending JP2009520685A (ja) | 2005-11-15 | 2006-11-13 | 化合物およびそれらの使用ｉｖ |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080293709A1 (enExample) |
| EP (1) | EP1957462A4 (enExample) |
| JP (1) | JP2009520685A (enExample) |
| KR (1) | KR20080070744A (enExample) |
| CN (1) | CN101360714A (enExample) |
| AR (1) | AR056217A1 (enExample) |
| AU (1) | AU2006316256A1 (enExample) |
| BR (1) | BRPI0618607A2 (enExample) |
| CA (1) | CA2629831A1 (enExample) |
| IL (1) | IL191057A0 (enExample) |
| NO (1) | NO20082481L (enExample) |
| TW (1) | TW200804290A (enExample) |
| UY (1) | UY29919A1 (enExample) |
| WO (1) | WO2007058583A2 (enExample) |
| ZA (1) | ZA200803859B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| SG162790A1 (en) | 2005-06-14 | 2010-07-29 | Schering Corp | Aspartyl protease inhibitors |
| CN101394852A (zh) | 2005-06-14 | 2009-03-25 | 先灵公司 | 作为蛋白酶抑制剂的化合物的制备和用途 |
| AU2006307314C1 (en) | 2005-10-25 | 2011-08-25 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| ES2476605T3 (es) | 2007-04-24 | 2014-07-15 | Shionogi & Co., Ltd. | Derivados de aminohidrotiazina sustituidos con grupos cíclicos |
| JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
| CN101868457B (zh) | 2007-09-24 | 2013-02-13 | 科门蒂斯公司 | 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物 |
| KR20100135711A (ko) * | 2007-12-20 | 2010-12-27 | 엔비보 파마슈티칼즈, 인코퍼레이티드 | 사중치환된 벤젠 |
| AU2009258496B8 (en) | 2008-06-13 | 2014-06-26 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| JP2012505241A (ja) | 2008-10-10 | 2012-03-01 | パーデュー・リサーチ・ファウンデーション | アルツハイマー病の治療用組成物 |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| JP2012509352A (ja) * | 2008-11-20 | 2012-04-19 | パーデュー・リサーチ・ファウンデーション | Ｂａｃｅ１のキナゾリン阻害剤および使用方法 |
| US8859590B2 (en) | 2008-12-05 | 2014-10-14 | Purdue Research Foundation | Inhibitors of BACE1 and methods for treating Alzheimer's disease |
| CN102725290B (zh) | 2009-07-27 | 2016-03-09 | 吉利德科学股份有限公司 | 作为离子通道调节剂的稠合杂环化合物 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| UA110467C2 (uk) | 2009-12-11 | 2016-01-12 | Шионогі Енд Ко., Лтд. | Похідні оксазину |
| WO2011077726A1 (ja) | 2009-12-24 | 2011-06-30 | 塩野義製薬株式会社 | ４－アミノ－１，３－チアジンまたはオキサジン誘導体 |
| PH12012502377A1 (en) | 2010-06-09 | 2014-10-14 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| ES2529119T3 (es) | 2010-07-02 | 2015-02-17 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| MX2013003246A (es) * | 2010-09-22 | 2013-05-22 | Janssen Pharmaceutica Nv | Derivados de 4, 7-dihidro-pirazolo [1, 5-a] pirazin-6-ilamina utiles como inhibidores de beta-secretasa (bace). |
| JP5766198B2 (ja) * | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| CN103261199A (zh) * | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
| NZ610948A (en) | 2010-12-22 | 2014-06-27 | Janssen Pharmaceutica Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| JP5853033B2 (ja) | 2011-03-01 | 2016-02-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な６，７−ジヒドロ−ピラゾロ［１，５−ａ］ピラジン−４−イルアミン誘導体 |
| BR112013022917A2 (pt) | 2011-03-09 | 2016-12-06 | Janssen Pharmaceutica Nv | derivados 3,4-dihidro-pirrolo[1,2-a]pirazino-1-ilamina úteis como inibidores de beta-secretase (bace) |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
| TWI510480B (zh) | 2011-05-10 | 2015-12-01 | Gilead Sciences Inc | 充當離子通道調節劑之稠合雜環化合物 |
| TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| JP6325092B2 (ja) | 2013-06-12 | 2018-05-16 | ヤンセン ファーマシューティカ エヌ．ベー． | βーセクレターゼ（ＢＡＣＥ）の阻害剤としての４−アミノ−６−フェニル−５，６−ジヒドロイミダゾ［１，５−Ａ］ピラジン誘導体 |
| KR102243133B1 (ko) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-6,7-디하이드로[1,2,3]트리아졸로[1,5-a]피라진 유도체 |
| KR102243135B1 (ko) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진-3(2h)-온 유도체 |
| EP3233834B1 (en) | 2014-12-18 | 2019-11-13 | Janssen Pharmaceutica NV | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine derivatives useful as inhibitors of beta-secretase |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4515696A (en) * | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| US5883102A (en) * | 1995-10-17 | 1999-03-16 | Astra Pharmaceuticals Limited | Pharmaceutically active compounds |
| NZ331932A (en) * | 1996-04-13 | 2000-02-28 | Astra Pharma Prod | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents |
| EP1474147B1 (en) * | 2001-12-07 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Pyrimidine-based compounds useful as gsk-3 inhibitors |
| AR053902A1 (es) * | 2005-06-14 | 2007-05-23 | Schering Corp | Inhibidores de aspartil proteasa heterociclicos macrociclicos |
-
2006
- 2006-11-08 TW TW095141352A patent/TW200804290A/zh unknown
- 2006-11-13 BR BRPI0618607-6A patent/BRPI0618607A2/pt not_active IP Right Cessation
- 2006-11-13 JP JP2008541110A patent/JP2009520685A/ja active Pending
- 2006-11-13 US US12/093,631 patent/US20080293709A1/en not_active Abandoned
- 2006-11-13 AR ARP060104956A patent/AR056217A1/es not_active Application Discontinuation
- 2006-11-13 AU AU2006316256A patent/AU2006316256A1/en not_active Abandoned
- 2006-11-13 WO PCT/SE2006/001283 patent/WO2007058583A2/en not_active Ceased
- 2006-11-13 CN CNA2006800511195A patent/CN101360714A/zh active Pending
- 2006-11-13 CA CA002629831A patent/CA2629831A1/en not_active Abandoned
- 2006-11-13 EP EP06813006A patent/EP1957462A4/en not_active Withdrawn
- 2006-11-13 KR KR1020087014418A patent/KR20080070744A/ko not_active Withdrawn
- 2006-11-14 UY UY29919A patent/UY29919A1/es not_active Application Discontinuation
-
2008
- 2008-04-27 IL IL191057A patent/IL191057A0/en unknown
- 2008-05-06 ZA ZA200803859A patent/ZA200803859B/xx unknown
- 2008-06-03 NO NO20082481A patent/NO20082481L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009520685A5 (enExample) | ||
| JP2009515949A5 (enExample) | ||
| US7425552B2 (en) | Pyridazinone compounds | |
| JP5934403B2 (ja) | ５，６−ジヒドロ−１ｈ−ピリジン−２−オン化合物 | |
| JP2010504346A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| JP2013528602A5 (enExample) | ||
| JP2007510689A5 (enExample) | ||
| JP2010534647A5 (enExample) | ||
| JP2008540637A5 (enExample) | ||
| JP2006525298A5 (enExample) | ||
| JP2009541311A5 (enExample) | ||
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| JP2007513915A5 (enExample) | ||
| RU2009133807A (ru) | Соединения амино-5-[замещенного-4-(дифторметокси)фенил]-5-фенилимидазолона в качестве ингибиторов бета-секретазы | |
| JP2009525340A5 (enExample) | ||
| JP2011528034A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| CA2737999A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | |
| JP2020526549A5 (enExample) | ||
| JP2020503293A5 (enExample) | ||
| JP2010500334A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| JP2004525183A5 (enExample) |